81 261

Cited 3 times in

Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial

Authors
 Cheol-Kyu Park  ;  Hyung-Joo Oh  ;  Seung Soo Yoo  ;  Shin Yup Lee  ;  Sang Hoon Lee  ;  Eun Young Kim  ;  Sung Yong Lee  ;  Juwhan Choi  ;  Min Ki Lee  ;  Mi-Hyun Kim  ;  Tae Won Jang  ;  Chaeuk Chung  ;  In-Jae Oh  ;  Young-Chul Kim 
Citation
 TRANSLATIONAL LUNG CANCER RESEARCH, Vol.11(8) : 1606-1618, 2022-08 
Journal Title
TRANSLATIONAL LUNG CANCER RESEARCH
ISSN
 2218-6751 
Issue Date
2022-08
Keywords
Adjuvant chemotherapy ; cisplatin ; non-small-cell carcinoma ; pemetrexed
Abstract
Background: We aimed to evaluate the efficacy of postoperative adjuvant pemetrexed plus cisplatin (Pem-Cis) in pathologic stage IB-IIIA lung adenocarcinoma (LUAD) patients.

Methods: A prospective, phase II study was performed in seven institutions in South Korea. Patients with completely resected stage IB-IIIA LUAD received pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2). Adjuvant treatments were administered every 3 weeks for 4 cycles. The primary endpoint was to prove the Pem-Cis's superiority in terms of 2-year disease-free survival rate (DFSR) compared with historical control without adjuvant chemotherapy (50%).

Results: Between August 2015 and February 2018, 105 patients were enrolled in this study. Approximately 31.4% (n=33), 43.8% (n=46), and 24.8% (n=26) of patients had pathologic stage IB, II, and IIIA, respectively. Most of the patients underwent lobectomy (n=98, 93.3%). Moreover, 41.1% and 12.1% of the patients had epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase rearrangement. Four cycles of Pem-Cis were administered in 99 patients (94.3%). At a median follow-up of 57.7 months, the 2-year DFSR was 78.1%. Multivariable analysis showed that pathologic stage IIIA and EGFR mutation were significant risk factors for DFS. Grade 3 adverse events occurred in 10 patients (9.5%), and leukopenia (n=3, 2.9%) was the most common adverse event.

Conclusions: Adjuvant Pem-Cis is superior to historical control without adjuvant treatment in terms of 2-year DFSR; the proportion of patients with stage IB and driver mutations were higher than that of patients in previous trials. Pem-Cis showed favorable tolerability as adjuvant chemotherapy (clinicaltrial.gov; Identifier: NCT02498860).
Files in This Item:
T202300835.pdf Download
DOI
10.21037/tlcr-22-183
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Eun Young(김은영) ORCID logo https://orcid.org/0000-0002-3281-5744
Lee, Sang Hoon(이상훈) ORCID logo https://orcid.org/0000-0002-7706-5318
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193248
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links